Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2024

Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2024

DelveInsight’s, “Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Respiratory Syncytial Virus (RSV): Understanding

Respiratory Syncytial Virus (RSV): Overview

RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults. RSV spreads through respiratory droplets and can survive on surfaces for several hours. While most infections are self-limiting, severe cases may require hospitalization, and preventive measures such as good hygiene and vaccination are essential in managing its spread.

Symptoms of RSV infection usually include runny nose; decrease in appetite; coughing; sneezing fever; wheezing. These symptoms usually appear in stages and not all at once. In very young infants with RSV, the only symptoms may be irritability, decreased activity, and breathing difficulties. RSV can also cause more severe infections such as bronchiolitis, an inflammation of the small airways in the lung, and pneumonia, an infection of the lungs. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age. People infected with RSV usually show symptoms within 4 to 6 days after getting infected.

Respiratory Syncytial Virus (RSV) pathophysiology involves the virus infecting and replicating in the epithelial cells of the respiratory tract. The virus causes cell fusion (syncytium formation) by expressing fusion proteins on its surface, leading to the destruction of infected cells and inflammation in the airways. This inflammatory response results in increased mucus production, airway swelling, and obstruction. In severe cases, RSV can lead to bronchiolitis and pneumonia, particularly in infants and young children, causing significant respiratory distress and impaired gas exchange. RSV is highly contagious and it spreads through droplet transmission. When a person with the infection coughs or sneezes, secretions from their respiratory tract containing the virus are passed out into the air. A person is usually contagious for 3 to 8 days, but young children and those with a weakened immune system may still be able to pass it on for up to 4 weeks, even after their symptoms disappear. People infected with RSV are usually contagious for 3 to 8 days. However, some infants, and people with weakened immune systems, can continue to spread the virus even after they stop showing symptoms, for as long as 4 weeks.

Diagnosis of Respiratory Syncytial Virus (RSV) primarily involves clinical evaluation based on symptoms such as wheezing, coughing, and difficulty breathing, particularly in infants and young children. Laboratory tests include antigen detection, polymerase chain reaction (PCR) assays, and viral culture from nasal or throat swabs. Rapid diagnostic tests can provide results within hours, aiding in the timely management of the infection. Chest X-rays and blood tests may be performed to assess the severity of the disease and rule out other conditions. Most RSV infections resolve on their own in a week or two. Antiviral drug called palivizumab is available to prevent severe RSV illness in high-risk infants (born prematurely or with congenital heart disease or chronic lung disease). However, the use of palivizumab is limited as it can only be used in certain children considered at high risk for complications, does not help cure or treat children already suffering from serious RSV disease, and cannot prevent RSV infection.

""Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Respiratory Syncytial Virus (RSV) pipeline landscape is provided which includes the disease overview and Respiratory Syncytial Virus (RSV) treatment guidelines. The assessment part of the report embraces, in depth Respiratory Syncytial Virus (RSV) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus (RSV) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory Syncytial Virus (RSV) R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory Syncytial Virus (RSV).

Respiratory Syncytial Virus (RSV) Emerging Drugs Chapters

This segment of the Respiratory Syncytial Virus (RSV) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Respiratory Syncytial Virus (RSV) Emerging Drugs

• Clesrovimab: Merck Sharp & Dohme

Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

• IVX A12: AstraZeneca

IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults ≥60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

• MV-012-968: Meissa Vaccines, Inc

MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naïve children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company’s proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

Further product details are provided in the report……..

Respiratory Syncytial Virus (RSV): Therapeutic Assessment

This segment of the report provides insights about the different Respiratory Syncytial Virus (RSV) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Respiratory Syncytial Virus (RSV)

There are approx. 50+ key companies which are developing the therapies for Respiratory Syncytial Virus (RSV). The companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. Phase III include, Merck Sharp & Dohme.

• Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Respiratory Syncytial Virus (RSV): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Respiratory Syncytial Virus (RSV) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Respiratory Syncytial Virus (RSV) drugs.

Respiratory Syncytial Virus (RSV) Report Insights

• Respiratory Syncytial Virus (RSV) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Respiratory Syncytial Virus (RSV) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Respiratory Syncytial Virus (RSV) drugs?
• How many Respiratory Syncytial Virus (RSV) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory Syncytial Virus (RSV)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Respiratory Syncytial Virus (RSV) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Respiratory Syncytial Virus (RSV) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Products

• Meissa Vaccines, Inc
• Enanta Pharmaceuticals
• Daiichi Sankyo Company
• AstraZeneca
• Codagenix, Inc
• Meissa Vaccines, Inc.
• Calder Biosciences
• Ark Biosciences
• Vicebio
• Immorna
• CastleVax
• Moderna Therapeutics

Key Products

• MV-012-968
• EDP-938
• VN-0200
• IVX A12
• RSV CodaVaxTM
• MV-012-968
• DT-PreF
• AK0611
• VXB 251
• mRNA combination vaccine
• CVAX 02
• mRNA 1345

Please Note: It will take 3-4 business days to complete the report upon order confirmation.